ALX ONCOLOGY HOLDINGS INC — Form 8-K
Filed October 15, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
ALX Oncology exchanged unspecified shares of common stock (surrendered by stockholders for no consideration) for pre-funded warrants to purchase an unspecified number of common shares at $0.001 exercise price per share, effective October 15, 2026. The exchange qualifies under Securities Act Section 3(a)(9); specific share counts and stockholder identities are redacted in the filing.
Why this rating
Routine recapitalization mechanics with redacted material terms; cannot assess magnitude without unredacted share counts relative to $18M market cap.
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.